Open in interactive viewer → charts, metric popovers & call review

Revenio Doubled Its Revenue and Stood Still

A deliberately dismantled US sales org, a nine-point gross-margin hole inherited from Visionix, and a trimmed top end of guidance — the quarter that was 'historic' only on the first line of the P&L.
REG1V.HE · Earnings Call · 2026-11-12

The scale mirage

Revenio's Q3 was, in Jouni Toijala's words, a historic quarter: net sales of €58.8 million against a comparable base roughly half that size, reported growth a shade under 130%, and the first full three months of the Visionix acquisition in the numbers. Strip out the arithmetic of the merger and the story inverts. On a pro-forma combined basis, organic growth was, in the CFO's own word, "basically flat" — and year-to-date organic growth was flat too. The gap between the two readings is the whole report. Gross margin fell to 63.2% from 71.5%, with Jukka Kainulainen attributing a full nine percentage points of that to Visionix's structurally lower margin profile, another two points to electronic component unit-cost inflation and mix, offset by roughly three points of US tariff refunds. Adjusted EBITDA of €8.7 million was 14.7% of sales versus 25.7% a year earlier. In absolute euros it rose more than 30%, which is the honest way to read it — but the company's headline profitability ratio has been halved by design, and management chose to make adjusted EBITDA the new headline KPI precisely so the optical dilution stops being the first thing investors see.

A wound the CEO chose to inflict

The most revealing passage of the call was Toijala's answer on why North America declined year-on-year against pro forma. Rather than blame the market, he owned it:

We would have been able to perform better in the U.S.A. from the sales perspective if we wouldn't have changed anything. But that wouldn't be positive for the long-term sustainable growth in the U.S.A.

Jouni Toijala, Group CEO · 2026-11-12
The new organization went live on 1 August: regions redrawn, territories re-scoped, the combined portfolio cross-trained into the sales and marketing team, with finance, control and HR swapped out alongside. The consequence showed up immediately in U.S. sales. Management frames it as a deliberate trade of one to two quarters of revenue for a platform that can actually sell the merged catalogue — tonometers, fundus imaging, perimetry, OCT, and Visionix's OEM multimodal devices — rather than two overlapping direct forces tripping over the same ophthalmology accounts. This deserves scrutiny because it directly contradicts the tone of the prior call. In September, Toijala was confident the old business was re-accelerating: “if we look how the Q3 has started, I mean, old Revenio back on the growth track.” — Jouni Toijala, CEO · 2026-09-08 Three months later, both halves of the company were flat and the top end of the guidance range was cut to €200 million from €205 million. Kainulainen was explicit about the cause — the APAC region continuing weak and the North American reorganisation both landing in H2. The APAC excuse is now entering its fifth or sixth consecutive quarter of repetition, which makes it less a cyclical headwind and more a structural characteristic of the business that management has yet to fix.

What is genuinely working

The balance sheet is the cleanest part of the story. Operating cash flow turned to €5.5 million from €3 million despite roughly €2 million of one-off integration payments, on strong working capital. At quarter-end net debt stood near €232 million against 5.1x net debt/EBITDA, with gearing at 149% and an equity ratio of 32% — all before October's oversubscribed rights issue, after which the €80 million bridge-to-equity facility has been repaid and leverage sits a little above 3x. The leverage metrics were the single biggest thing weighing on the equity, and they have been materially defused. Synergy delivery is running ahead of the promised pace, with 25% of the €20 million EBITDA uplift secured on a run-rate basis — the first €5 million, all from OpEx, not commercial. Which is precisely why the retiral of the EBITDA uplift keyword from the top of the company's vocabulary is notable: it was the second-ranked term last quarter and has fallen out entirely as the story migrates from "we will find the savings" to "we must now prove the cross-sell." Asked directly whether cross-selling wins had appeared, Toijala conceded "not yet too much on Q3, but the pipeline building, yes."

Loose threads and slippage

Three items deserve flagging. First, ILLUME, the company's own AI-driven diabetic retinopathy software, slipped again: guidance is now Q3–Q4 2027 versus the "second half, hopefully Q3 2027" offered in September, itself a step back from an original first-half 2027 target. The partial offset is that the DRSplus device got cleared alongside the third-party iHealthScreen algorithm, so Revenio can sell DR screening in the US today — but with someone else's software. Second, a cybersecurity intrusion into an internal Visionix server, disclosed pre-call, with management insisting it was contained and had no IP, patient-data or financial consequence. Third, roughly €2 million of tariff refunds arrived in the quarter — a tidy three-point gross margin gift that is distinctly non-recurring in nature. This is not idiosyncratic: tariff refund was the single hottest keyword across the entire market two quarters ago, and a string of reporters from Stanley Black & Decker to Levi's has booked the same windfall. Revenio is riding a wave here, not building one, and management refuses to forecast further recoveries. The rhetoric is worth a final note. The phrase different company recurred throughout the prepared remarks as a shield: we cannot be judged as the old tonometer business because we are no longer it. That is fair — the old Revenio was a ~70% gross-margin, high-twenties EBITDA-margin compounder; the new one is a 63% gross-margin, mid-teens margin medtech with €232 million of gross debt and an integration to finish. But markets eventually judge companies on what they are, not what they were. With organic growth at zero, cross-sell unproven, the US reorganisation only two months old and the flagship AI product pushed into late 2027, the burden of proof for 2027 rests entirely on delivery that has not yet shown up in a single line of the P&L. “no impact to the operations, no impact to the financial performance, and no loss of IP” — Jouni Toijala, Group CEO · 2026-11-12 is the right answer on the cyber incident. The harder question is whether the same sentence will be true of the reorganisation by the time Q4 — described by the CEO as seasonally critical — is reported.